8-K: Nektar's Rezpegaldesleukin Shows Durable Efficacy in AD

Nektar Therapeutics announced positive 36-week maintenance data for rezpegaldesleukin in moderate-to-severe atopic dermatitis, demonstrating sustained and deepening responses with a favorable safety profile.

Summary

• Nektar Therapeutics reported positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD).
• The global Phase 2b study enrolled 393 patients, with those achieving Eczema Area Severity Index (EASI) percent score reductions of at least 50 after a 16-week induction period re-randomized to monthly (Q4W) or quarterly (Q12W) dosing.
• Both Q4W and Q12W dosing regimens resulted in sustained disease control for EASI-75, EASI-90, validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS) response at Week 52.
• The 24 ug/kg Q4W and Q12W regimens demonstrated the highest maintenance of response, with a 2 to 5-fold increase in patients achieving EASI-100.
• Among all re-randomized patients, Q4W dosing increased EASI-100 response from 4% to 22%, and Q12W dosing increased EASI-100 response from 9% to 18%.
• The safety profile of rezpegaldesleukin was consistent with the induction part of the study, showing good tolerability with no new safety concerns identified.
• The discontinuation rate due to adverse events was low at 3.5% for all aggregated patients, and injection site reactions, the most frequent adverse event, were nearly all mild (77%) with a 0.7% discontinuation rate.
• Nektar reached alignment with the U.S. Food and Drug Administration (FDA) on evaluating a 24 ug/kg Q2W rezpegaldesleukin dose regimen for a 24-week induction period in two planned Phase 3 registrational trials.
• Phase 3 trials will include co-primary endpoints of EASI-75 and an IGA-related endpoint, along with a 36-week maintenance period evaluating 24 ug/kg Q4W and 24 ug/kg Q12W regimens.
• The company plans to initiate Phase 3 trials in the second quarter of 2026 and is targeting a Biologics License Application (BLA) filing in 2029.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, validating the novel Treg mechanism with strong efficacy and safety data, and providing a clear, accelerated path to Phase 3 trials and potential BLA filing. The competitive advantages in safety and dosing frequency are particularly noteworthy.

Positives

• Durable and new responses were observed across key disease measurements (EASI-75, EASI-90, vIGA-AD 0/1, Itch NRS) with both monthly and quarterly dosing regimens.
• High maintenance of EASI-75 responses was achieved by 71% of patients on 24 ug/kg Q4W and 83% on 24 ug/kg Q12W at Week 52.
• Maintenance of vIGA-AD 0/1 responses was 85% for 24 ug/kg Q4W and 63% for 24 ug/kg Q12W at Week 52.
• A significant 2 to 5-fold increase in EASI-100 (complete clearance) response rates was observed in the 24 ug/kg Q4W and Q12W dosing regimens.
• The safety profile was favorable, consistent with previous observations, well-tolerated, with no new safety concerns identified during the 36-week maintenance and escape periods.
• The discontinuation rate due to adverse events was low at 3.5%, and injection site reactions, while frequent, were mostly mild (77%) with a very low discontinuation rate of 0.7%.
• Alignment was reached with the FDA on the Phase 3 trial design, including the induction dose (24 ug/kg Q2W for 24 weeks) and co-primary endpoints (EASI-75 and IGA-related endpoint), providing a clear regulatory path.
• The novel regulatory T-cell (Treg) mechanism of rezpegaldesleukin is validated for deep and durable efficacy.
• No increased risk of conjunctivitis, oral herpes, oral ulcers, or malignancies was observed, differentiating it from other mechanisms.
• Rapid onset of EASI-75 response and itch relief was seen early in treatment during the induction phase.
• Meaningful improvement in self-reported asthma control was observed in patients with co-morbid asthma.

Risks

• The therapeutic potential of rezpegaldesleukin is based on preclinical and clinical findings and observations and is subject to change as research and development continue.
• Rezpegaldesleukin is an investigational agent, and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical studies.
• The risk of failure for rezpegaldesleukin is high and can unexpectedly occur at any stage prior to regulatory approval.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, or competitive factors.
• Failure to ultimately obtain regulatory approval in one or more important markets remains a significant risk.
• Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Other risk factors are described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and any other future SEC filings.

Future Outlook

Nektar Therapeutics plans to initiate two Phase 3 registrational trials for rezpegaldesleukin in moderate-to-severe atopic dermatitis in the second quarter of 2026. These trials will evaluate a 24 ug/kg Q2W induction regimen for 24 weeks, with co-primary endpoints of EASI-75 and an IGA-related endpoint, followed by a 36-week maintenance period assessing 24 ug/kg Q4W and Q12W regimens. The company aims to file a Biologics License Application (BLA) in 2029. Upcoming milestones include additional REZOLVE-AD data submissions, further efficacy and safety analyses in Q3 2026, translation data presentation in Q3 2026, 52-week REZOLVE-AA data in Q2 2026, NKTR-0165 preclinical data in H2 2026, NKTR-255 data at ASCO-GU in late February 2026, and initial data from a Phase 2 study in Type 1 Diabetes in 2027.

Management Comments

• Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, stated that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis, with new and sustained responses observed across key endpoints and a large proportion of patients achieving complete clearance.
• David Rosmarin M.D., Chair, Department of Dermatology and Associate Professor of Dermatology, Indiana University School of Medicine, highlighted that rezpegaldesleukin offers a completely novel therapeutic modality with numerous advantages, noting the absence of increased risk for conjunctivitis, oral herpes, oral ulcers, or malignancies, and expressed eagerness to initiate Phase 3 studies quickly.
• Howard W. Robin, President and CEO of Nektar Therapeutics, emphasized that the REZOLVE-AD study results reinforce the promise of the Treg mechanism, showcasing compelling efficacy and safety advantages, including rapid onset of EASI-75 response and itch relief, improved asthma control in co-morbid patients, and less frequent maintenance dosing compared to current mechanisms, with a goal of BLA submission in 2029.

Industry Context

StockSavvy.ai notes that rezpegaldesleukin's novel regulatory T-cell (Treg) mechanism differentiates it from existing and in-development biologics that often target individual cytokine pathways (e.g., IL-13, OX-40, JAK inhibitors). By acting as a master immune-modulator, rezpegaldesleukin aims to reestablish immune homeostasis, potentially offering a broader and more fundamental approach to treating atopic dermatitis. The observed favorable safety profile, particularly the absence of increased risk for conjunctivitis, oral herpes, oral ulcers, or malignancies, positions it advantageously against some competitors. Furthermore, the potential for less frequent maintenance dosing (quarterly) could be a significant competitive advantage in terms of patient convenience and adherence, which are critical factors in chronic disease management.

Comparison to Industry Standards

• Maintenance of EASI-75 at Week 52 for rezpegaldesleukin (71% for 24 ug/kg Q4W, 83% for 24 ug/kg Q12W) compares favorably to historically reported data for Dupilumab (IL-13 SOC, 300mg QW/Q2W induction) at 67% and Amlitelimab (OX-40, 250mg Q4W+LD induction) at 50% in cross-trial comparisons.
• Maintenance of vIGA-AD 0/1 at Week 52 for rezpegaldesleukin (85% for 24 ug/kg Q4W, 63% for 24 ug/kg Q12W) compares favorably to historically reported data for Dupilumab (IL-13 SOC) at 52% and Amlitelimab (OX-40) at 45% in cross-trial comparisons.
• The safety profile of rezpegaldesleukin, with no observed increased risk of conjunctivitis, oral ulcers, or infections (including oral herpes), is highlighted as an advantage over IL-13, OX-40, and JAK inhibitor classes, which have reported such adverse events.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, clear regulatory path to Phase 3, and potential for future market entry, which could enhance company valuation.
• Patients with moderate-to-severe atopic dermatitis: Potential for a novel, effective, and well-tolerated treatment option with the added benefit of less frequent maintenance dosing (monthly or quarterly).
• Healthcare providers: A new therapeutic modality that could offer a differentiated treatment approach for a challenging chronic condition.
• Regulatory authorities: Progress towards a potential new drug approval for a significant unmet medical need.

Next Steps

• Start Phase 3 trials for rezpegaldesleukin in moderate-to-severe atopic dermatitis in Q2 2026.
• Submit additional data from the REZOLVE-AD study for a medical meeting.
• Conduct additional analysis of REZOLVE-AD efficacy and safety from the maintenance period, planned for Q3 2026.
• Present translation data, planned for Q3 2026.
• Announce 52-week data from the REZOLVE-AA study in alopecia areata in Q2 2026.
• Present preclinical data for NKTR-0165 (TNFR2 agonist antibody) at a scientific conference in H2 2026.
• Present JAVELIN Bladder Medley Study data (NKTR-255) at the 2026 ASCO-GU conference at the end of February 2026.
• Anticipate 52-week data from the REZOLVE-AD off-treatment part of the study (to evaluate remittive effect) in Q1 2027.
• Anticipate initial data from the TrialNet sponsored Phase 2 study in Type 1 Diabetes in 2027.
• Target a Biologics License Application (BLA) filing in 2029.

Key Dates

Recommendation

The strong positive results from the REZOLVE-AD maintenance study, demonstrating durable efficacy and a favorable safety profile for rezpegaldesleukin, significantly de-risk the program. Alignment with the FDA on Phase 3 trial design provides a clear and accelerated path to market. The novel Treg mechanism and potential for less frequent dosing offer a competitive advantage in the atopic dermatitis market, making this a compelling investment opportunity for long-term growth.

Keywords

Nektar Therapeutics, rezpegaldesleukin, atopic dermatitis, eczema, Phase 2b, clinical trial, Treg biologic, FDA, Phase 3, dermatology, immunology, NKTR